Conectividad de Java con bases de datos mediante invocación de objetos con métodos remotos (objetos RMI)

El desarrollo de aplicaciones distribuidas está teniendo cada vez más auge entre las empresas del mundo; esto se debe a la gran importancia que ha adquirido el Internet en los últimos años. Para dar solución a esta necesidad surgen arquitecturas distribuidas como RMI (Invocaci6n de Métodos Remotos). En este artículo se describe una de las principales arquitecturas empleadas para desarrollar aplicaciones basadas en objetos distribuidos, Java RMI. Además se presenta una comparación entre esta arquitectura y otras como CORBA, RPC y DCOM

Mapas de contorno de tasa de precipitación y atenuación por lluvias para planificación preliminar de enlaces del satélite "Simón Bolívar" en Venezuela

YNA DOI: https://doi.org/10.15446/dyna.v86n209.73774 DYNA, Volumen 86, Número 209, p. 30-39, 2019. ISSN electrónico 2346-2183. ISSN impreso 0012-7353. Rainfall rate and rain attenuation contour maps for preliminary “Simon Bolivar” satellite links planning in Venezuela Mapas de contorno de tasa de precipitación y atenuación por lluvias para planificación preliminar de enlaces del satélite "Simón Bolívar" en Venezuela Angel Dario Pinto Mangones, Nelson Alexander Pérez García, Juan Manuel Torres Tovio, Eduardo José Ramírez, Samir Oswaldo Castaño Rivera, Jaime Velez Zapata, John Dwiht Ferreira Rodríguez, Leidy Marian Rujano Molina Texto completo: PDF (English) Bookmark and Share Resumen (en_US) Predicting precipitation rate and rainfall attenuation are key aspects in planning and dimensioning of wireless communications systems operating at frequencies above 10 GHz, such as satellite communication systems at Ku and Ka bands. In this paper, contour maps of rainfall rate and rain attenuation are developed for the first time in Venezuela, based on 1-min rain rate statistics obtained from measurements carried out in Venezuela over at least 30 years period with a higher integration time and using Rice-Holmberg model, refined Moupfouma-Martin model and Recommendation ITU-R P.837-7, for rain rate estimation and Recommendation ITU-R P.618-13, Ramachandran-Kumar model, Yeo-Lee-Ong model and Rakshit-Adhikari-Maitra model, for rain attenuation prediction in “Simon Bolivar” satellite links in Venezuela. The overall results of both types of maps represent a useful tool for preliminary planning of those links in the country, specifically, in Ku and Ka bands.La tasa de precipitación y la atenuación por lluvias son aspectos claves en la planificación y dimensionamiento de sistemas inalámbricos de comunicaciones que operan en frecuencias superiores a 10 GHz, tales como los sistemas de comunicación vía satélite en las bandas Ku y Ka. En este artículo, se desarrollan por primera vez en Venezuela mapas de contorno de tasa de precipitación y atenuación por lluvias, en base a estadísticas de lluvia de 1-minuto obtenidas a partir de mediciones realizadas en Venezuela en un periodo de al menos 30 años con alto tiempo de integración y usando los modelos Rice-Holmberg, Moupfouma-Martin refinado y Recomendación ITU-R P.837-7, para la estimación de la precipitación y los modelos Recomendación ITU-R P.618-13, Ramachandran-Kumar, Yeo-Lee-Ong y Rakshit-Adhikari-Maitra, para la predicción de la atenuación por lluvias para enlaces del satélite “Simón Bolívar” en Venezuela. Los resultados generales de ambos tipos de mapas representan una herramienta útil para la planificación preliminar de dichos enlaces en el país, específicamente, en las bandas Ku y Ka

Measurement of the cosmic ray spectrum above 4×10184{\times}10^{18} eV using inclined events detected with the Pierre Auger Observatory

A measurement of the cosmic-ray spectrum for energies exceeding $4{\times}10^{18}$ eV is presented, which is based on the analysis of showers with zenith angles greater than $60^{\circ}$ detected with the Pierre Auger Observatory between 1 January 2004 and 31 December 2013. The measured spectrum confirms a flux suppression at the highest energies. Above $5.3{\times}10^{18}$ eV, the "ankle", the flux can be described by a power law $E^{-\gamma}$ with index $\gamma=2.70 \pm 0.02 \,\text{(stat)} \pm 0.1\,\text{(sys)}$ followed by a smooth suppression region. For the energy ($E_\text{s}$) at which the spectral flux has fallen to one-half of its extrapolated value in the absence of suppression, we find $E_\text{s}=(5.12\pm0.25\,\text{(stat)}^{+1.0}_{-1.2}\,\text{(sys)}){\times}10^{19}$ eV.Comment: Replaced with published version. Added journal reference and DO

Performance of the CMS Cathode Strip Chambers with Cosmic Rays

The Cathode Strip Chambers (CSCs) constitute the primary muon tracking device in the CMS endcaps. Their performance has been evaluated using data taken during a cosmic ray run in fall 2008. Measured noise levels are low, with the number of noisy channels well below 1%. Coordinate resolution was measured for all types of chambers, and fall in the range 47 microns to 243 microns. The efficiencies for local charged track triggers, for hit and for segments reconstruction were measured, and are above 99%. The timing resolution per layer is approximately 5 ns

Performance and Operation of the CMS Electromagnetic Calorimeter

The operation and general performance of the CMS electromagnetic calorimeter using cosmic-ray muons are described. These muons were recorded after the closure of the CMS detector in late 2008. The calorimeter is made of lead tungstate crystals and the overall status of the 75848 channels corresponding to the barrel and endcap detectors is reported. The stability of crucial operational parameters, such as high voltage, temperature and electronic noise, is summarised and the performance of the light monitoring system is presented

Microalgal biorefineries

ABSTRACT: Microalgae-based bioproducts remain expensive mainly due to microalgae cultivation, harvesting, and downstream processing costs. Nonetheless, microalgae are a high potential source of several biofuels, biofertilizers, and bioproducts (e.g., carbohydrates, long-chain fatty acids, pigments, and proteins), which can provide important nutritional, cosmetical, pharmaceutical, and health benefits. In addition, they are able to perform wastewater bioremediation and carbon dioxide mitigation. This not only contributes to a more sustainable microalgae production, with environmental benefits, but also offers cost savings on the whole process. Hence, from these small cellular factories, a large source of compounds and products can be obtained, providing a real microalgal-based biorefinery. This type of approach is crucial for the full application and commercialization of microalgae in a large range of products and industries, with added benefits for bioeconomy and society in general. This chapter addresses the potential transformation of microalgal biomass into a wide range of marketable products, presenting examples of experimental microalgae-based biorefineries grown in an autotrophic mode at a laboratory scale.info:eu-repo/semantics/publishedVersio

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. Methods In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH,non-alcoholic fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2–F3, or F1 with at least oneaccompanying comorbidity, were randomly assigned using an interactive web response system in a 1:1:1 ratio to receive oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily. Patients were excluded if cirrhosis, other chronic liver disease, elevated alcohol consumption, or confounding conditions were present. The primary endpointsfor the month-18 interim analysis were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resolution with no worsening of fibrosis, with the study considered successful if either primary endpoint was met. Primary analyses were done by intention to treat, in patients with fibrosis stage F2–F3 who received at least one dose of treatment and reached, or would have reached, the month 18 visit by the prespecified interim analysis cutoff date. The study also evaluated other histological and biochemical markers of NASH and fibrosis, and safety. This study is ongoing, and registered with ClinicalTrials.gov, NCT02548351, and EudraCT, 20150-025601-6. Findings Between Dec 9, 2015, and Oct 26, 2018, 1968 patients with stage F1–F3 fibrosis were enrolled and received at least one dose of study treatment; 931 patients with stage F2–F3 fibrosis were included in the primary analysis (311 in the placebo group, 312 in the obeticholic acid 10 mg group, and 308 in the obeticholic acid 25 mg group). The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0·045), and 71 (23%) in the obeticholic acid 25 mg group (p=0·0002). The NASH resolution endpoint was not met (25 [8%] patients in the placebo group, 35 [11%] in the obeticholic acid 10 mg group [p=0·18], and 36 [12%] in the obeticholic acid 25 mg group [p=0·13]). In the safety population (1968 patients with fibrosis stages F1–F3), the most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in the obeticholic acid 10 mg group, and 336 [51%] in the obeticholic acid 25 mg group); incidence was generally mild to moderate in severity. The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group). Interpretation Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. The results from this planned interim analysis show clinically significant histological improvement that is reasonably likely to predict clinical benefit. This study is ongoing to assess clinical outcomes